Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 506 | 33% |
| 2020 | 5 | 370 | 36% |
| 2021 | 12 | 400 | 39% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 89% of the cases CMS names in New Jersey; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 32 | 1,028−1.4%/yr | −1.4%/yr | 0.7 | 32% | 980 in 2030−0.7%/yr |
| New York | 12 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 112 | 6,842−0.4%/yr | −0.4%/yr | 6.30.8× | 86% | 9,070 in 2030+4.8%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
| 2024 |
| 392 |
| 45% |
| 2025 est. | ≈ 420 | – |
| 2026 est. | ≈ 420 | – |
| 2022 | 9 | 395 | 41% |
| 2023 | 11 | 430 | 43% |
| 2024 | 12 | 392 | 45% |
| 2025 from claims | – | 416 336–488 | 46% |
| 2026 forecast | – | 422 331–530 | 46% |
| 2027 forecast | – | 428 317–566 | 47% |
| 2028 forecast | – | 434 307–599 | 47% |
| 2029 forecast | – | 440 299–630 | 47% |
| 2030 forecast | – | 446 292–661 | 48% |
In 2025, 30% hospital outpatient, 70% surgery center. The share outside the hospital has moved +16 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~420 | ~120 | ~300 |
| 2027 · ~430 | ~120 | ~310 |
| 2028 · ~430 | ~120 | ~320 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 73% (70% in 2025), hospital outpatient about 27% (30% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| 563−6.5%/yr |
| −6.5%/yr |
| 0.3 |
| 16% |
| 550 in 2030−0.3%/yr |
| Massachusetts | 5 | 264−7.2%/yr | −7.2%/yr | 0.3 | 15% | 380 in 2030+6.4%/yr |
| New Hampshire | 2 | 101+2.3%/yr | +2.3%/yr | 0.4 | 46% | 190 in 2030+11%/yr |
| 8 |
| 739+5.9%/yr |
| +5.9%/yr |
| 0.70.9× |
| 58% |
| 950 in 2030+4.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Biotronik leads with 19% of company spending on these surgeons in 2025, +8 pts on 2024.
In 2025, 10 companies reported engagement with New Jersey’s surgeons worth $451K in consulting, speaking, meals and travel tied to these products, about $38K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.